Recent Investment Analysts’ Ratings Changes for Ascendis Pharma A/S (ASND)

Posted by Maddie Sorensen on Nov 21st, 2023

A number of firms have modified their ratings and price targets on shares of Ascendis Pharma A/S (NASDAQ: ASND) recently:

11/9/2023 – Ascendis Pharma A/S had its price target raised by analysts at Morgan Stanley from $113.00 to $116.00. They now have an “equal weight” rating on the stock.
11/8/2023 – Ascendis Pharma A/S was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
11/8/2023 – Ascendis Pharma A/S had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $192.00 price target on the stock.
10/31/2023 – Ascendis Pharma A/S had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $192.00 price target on the stock.
10/30/2023 – Ascendis Pharma A/S was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
10/9/2023 – Ascendis Pharma A/S had its “buy” rating reaffirmed by analysts at HC Wainwright.
10/5/2023 – Ascendis Pharma A/S is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $93.76 on Tuesday. The company has a quick ratio of 2.56, a current ratio of 3.44 and a debt-to-equity ratio of 7.39. Ascendis Pharma A/S has a 52 week low of $64.33 and a 52 week high of $127.77. The business has a 50-day simple moving average of $93.12 and a two-hundred day simple moving average of $92.31. The stock has a market cap of $5.41 billion, a price-to-earnings ratio of -8.25 and a beta of 0.48.

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last announced its quarterly earnings results on Tuesday, September 5th. The biotechnology company reported ($2.35) EPS for the quarter, beating analysts’ consensus estimates of ($2.68) by $0.33. Ascendis Pharma A/S had a negative return on equity of 570.61% and a negative net margin of 391.76%. The company had revenue of $51.59 million during the quarter, compared to analyst estimates of $41.73 million. On average, analysts expect that Ascendis Pharma A/S will post -9.8 EPS for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors have recently modified their holdings of ASND. Coppell Advisory Solutions LLC bought a new stake in shares of Ascendis Pharma A/S in the 2nd quarter valued at approximately $45,000. Bessemer Group Inc. bought a new stake in shares of Ascendis Pharma A/S in the 1st quarter valued at approximately $58,000. Clearstead Advisors LLC bought a new stake in shares of Ascendis Pharma A/S in the 1st quarter valued at approximately $66,000. SkyView Investment Advisors LLC bought a new stake in shares of Ascendis Pharma A/S in the 2nd quarter valued at approximately $66,000. Finally, BNP Paribas Arbitrage SA bought a new stake in shares of Ascendis Pharma A/S in the 2nd quarter valued at approximately $67,000.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia.